Are you a runner? Please join our #Run4HepB team and make your miles matter at the NYC Marathon on November 3! Learn more.


Hepatitis B Foundation, Blumberg Institute and PABC congratulates John Crowley of Amicus on being named BIO President and CEO

John Ron Jim 17Oct2023

Jim Greenwood (left), John Crowley (center) and Dr. Randall Hyer

Doylestown, Dec. 5, 2023Louis P. Kassa III, MPA, CEO of the Hepatitis B Foundation, Baruch S. Blumberg Institute and Pennsylvania Biotechnology Center (PABC), today described the choice of John F. Crowley, JD, MBA, executive chairman, Amicus Therapeutics, to be president and CEO of BIO, as “a brilliant decision that produce tangible benefits to the biotech industry.” 

“John Crowley is one of the most influential executives in the field of drug development and his personal story has been an inspiration to many, many people worldwide,” Kassa said. “He’s one more example of our region’s leadership in biotech, the life sciences and health care. On behalf of our three organizations, I want to congratulate John on this exciting new opportunity. 

BIO describes itself as the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the U.S. and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. 

Crowley was a panelist at the Oct. 17 event honoring Jim Greenwood of Bucks County, who is a former Congressman and was CEO of BIO from 2005 to 2020. 

Along with Crowley and Greenwood, Ron Philip, chief executive officer of Spark Therapeutics, participated in the Oct. 17 panel discussion, which was moderated by Randall N. Hyer, MD, PhD, MPH, president of the Baruch S. Blumberg Institute, which operates the PABC, and CEO of Merlin Biotech. 

About the Hepatitis B Foundation: We are the leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. Founded in 1991, the Hepatitis B Foundation is based in Doylestown, Pa., with offices in Washington, D.C., and Philadelphia. To learn more, go to, read our blog at, follow us on Twitter, Instagram and Facebook (@hepbfoundation) or contact us through 

About the Baruch S. Blumberg Institute: An independent, nonprofit research organization, the Blumberg Institute was launched in 2003 by the Hepatitis B Foundation to advance its research mission. Today, the Institute is a leading center for translational research in hepatitis B and liver cancer. The Institute supports drug discovery, biomarker discovery and translational biotechnology around common research themes such as chronic hepatitis, liver disease and liver cancer in an environment conducive to interaction, collaboration and focus. The Blumberg Institute is located in the Pennsylvania Biotechnology Center, which it manages, near Doylestown, Pa. and follow us on Twitter @BlumbergInstit1. 

About the Pennsylvania Biotechnology Center (PABC): The PABC uses a highly successful services-based approach to nurture and guide its member companies to success, advance biotechnology, maximize synergies among nonprofit scientists and their commercial colleagues. The PABC has nearly 100 member companies and organizations, mostly small to mid-size science, research and pharmaceutical companies. Nearly 50 of those companies operate on the Doylestown campus, which is home to the Hepatitis B Foundation and the Blumberg Institute. The PABC also manages B+labs at Cira Centre, a new incubator in Philadelphia, in partnership with Brandywine Realty Trust. PABC companies have produced numerous FDA-approved drugs and medical devices, and a recent study found that the PABC’s economic impact exceeded $7.3 billion and created more than 1,100 new jobs during 2016-2021. Please visit our website and follow us on LinkedIn, Instagram, Twitter (@BiotechnologyPa) and Facebook